Cyfuse Biomedical KK (TSE:4892) Total Long-Term Assets: 円331.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4892 Cyfuse Biomedical KK TSE:4892
59 GF Score
Price 円546.00
GF Value 円2,081.98
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK Total Long-Term Assets?

Cyfuse Biomedical KK TSE:4892 +2.82% 59 Total Long-Term Assets is 円331.6 Mil as of Dec. 2025. GuruFocus rates TSE:4892 with a GF Score™ of 59/100 and a GF Value™ of 円2,081.98 (Possible Value Trap). The stock has 5 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Cyfuse Biomedical KK's Total Long-Term Assets for the quarter that ended in Dec. 2025 was 円331.6 Mil.

Cyfuse Biomedical KK Total Long-Term Assets Related Terms

Cyfuse Biomedical KK Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK Total Long-Term Assets Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial 87.61 249.99 227.37 277.89 331.56

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 304.11 368.77 353.12 331.56 311.41
TSE:4892
59GF Score
Cyfuse Biomedical KK TSE:4892
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of 円331.6 Mil mean?
Cyfuse Biomedical KK (TSE:4892) has a Total Long-Term Assets of 円331.6 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Cyfuse Biomedical KK and its competitors.
Is Cyfuse Biomedical KK's Total Long-Term Assets too high?
Cyfuse Biomedical KK's current Total Long-Term Assets is 円331.6 Mil. Overall, Cyfuse Biomedical KK has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Total Long-Term Assets compare to ZTS?
Cyfuse Biomedical KK's Total Long-Term Assets of 円331.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Cyfuse Biomedical KK and its competitors. Cyfuse Biomedical KK's current Total Long-Term Assets is 円331.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,081.98, compared to a current price of 円546.00 — trading 73.8% below its estimated fair value. The current Total Long-Term Assets is 円331.6 Mil. Cyfuse Biomedical KK's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Total Long-Term Assets is 円331.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円546.00 is trading 73.8% below its estimated GF Value™ of 円2,081.98. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for TSE:4892:

  • Total Long-Term Assets: 円331.6 Mil
  • GF Value™: 円2,081.98 vs. price of 円546.00 (73.8% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Other Exchanges 4892:Japan
Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
59GF Score

Get the complete analysis for TSE:4892

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円546.00
Price
円2,081.98
GF Value